Thus, our studies suggest that arsenic trioxide may be repurposed as a ccRCC anticancer drug and pave the way for further investigation into the clinical utility of targeting PML to improve ccRCC outcome. The gene discussed is PML; the disease is nonpapillary renal cell carcinoma.